Our Goals are Anything but Artificial, Together we will Innovate with Intelligence.


AlphaMeld® is decoding the Gut-Brain Axis (GBA) and inflammasome pathways to drive a pipeline of therapies addressing chronic inflammatory diseases of the gut based on high unmet medical need, while maximizing localized efficacy and reducing systemic side-effects compared with the current standard of care.

News and Events

See More
InveniAI and Shionogi Enter AI-Powered...

Teams will work together by leveraging InveniAI's technology

April 27, 2021

InveniAI and Kyowa Kirin Enter...

Expansion of existing collaboration will leverage InveniAI

December 09, 2020

InveniAI and PRISM Biolab Initiate A…

Guilford, Conn., September 9, 2020, InveniAI® LLC (InveniAI), a global leader in pioneering the application of artificial

September 09, 2020

InveniAI Enters Strategic Artificial...

Three-year strategic collaboration to leverage InveniAI’s AI

July 29, 2020